King Street Properties has fully leased a 214,440-sf research facility in Lexington, Mass., to four pharmaceutical companies. Designed by R E Dinneen Architects & Planners, the four-story building will offer leading-edge lab and office environments for biomedical research. JLL is the leasing agent for the development, which has yet to open. Tenants include:
Fujifilm Diosynth Biotechnologies broke ground in August of 2020 on the $55 million Advanced Therapies Innovation Center in College Station, Texas. Representing an expansion of Fujifilm's cGMP manufacturing campus, the 60,000-sf facility will feature dedicated labs for process development and innovation. Research environments with BSL-2 capabilities will integrate advanced technologies for upstream, downstream, and analytical development.
Codiak BioSciences is constructing a 12,000-sf clinical manufacturing center in Lexington, Mass. The project includes the build-out of a leased lab and office building to create a GMP facility for the production of exosome therapeutics. Codiak is incorporating G-CON Manufacturing's PODs into the center to provide flexible cleanroom capacity. The prefabricated units offer exceptional scalability and mobility, and can be easily repurposed to meet future needs.
CRISPR Therapeutics signed a full-building lease in July of 2020 for a 263,500-sf facility in Boston's Seaport district. Breakthrough Properties is the developer for the project, which was designed by Payette to provide best-in-class laboratory environments for life science research. Both LEED Gold and Fitwel certification will be sought for the structure, which will offer multiple amenities including outdoor terraces and a fitness center.
The Cell and Gene Therapy Catapult is planning to create the Manufacturing Innovation Centre in Braintree in the United Kingdom. Supported by £100 million in government funding, the project will enable mass production of a COVID-19 vaccine. An existing pharmaceutical plant has been purchased from Benchmark Holdings at a cost of £16 million. The structure's GMP infrastructure for antigen production, formulation, process development, and scale manufacturing will be repurposed and enhanced. Completion is expected in December of 2021.
DiNAQOR AG completed construction in July of 2020 on a 9,687-sf R&D center in Schlieren, Switzerland. Located in the Bio-Technopark Schlieren-Zürich, the BSL-2 facility will enable DiNAQOR to fast-track the development of its human-induced pluripotent stem cells (iPSC) and engineered heart tissue platform. Accelerating the creation of next-generation genetic medicine methodologies, the project also provides sophisticated infrastructure to further optimize the company's proprietary locoregional heart perfusion approach.
Winstanley Enterprises is planning to build a $100 million bioscience research building in New Haven, Conn. Designed by Elkus Manfredi Architects, the 10-story, 500,000-sf facility will provide leasable laboratory and office environments for life science companies and academic institutions. Featuring a large public plaza, the project will include a conference center, a 50,000-sf business incubator, and a classroom for K-12 educational programs.
MilliporeSigma, a subsidiary of Merck, is planning to expand its existing campus in Buchs, Switzerland, with the construction of a $20 million laboratory for the company's reference materials business. Accommodating 40 employees, the three-story, 12,000-sf structure will provide analytical and R&D suites for the testing of pharmaceuticals, environmental materials, and food and beverage products.
SiO2 Materials Science is investing $163 million to expand its production capacity for vaccine vials and syringes in Auburn, Ala. The company will increase the footprint of its existing facility in the Auburn Technology Park West to create a 70,000-sf manufacturing center with additional space for precision injection molding operations. A second molding plant will also be constructed nearby.
University Hospital Hamburg-Eppendorf is planning to build a 193,000-sf translational medicine hub in Hamburg, Germany. Housing the Campus Research II facility and the Hamburg Center for Translational Immunology, the interdisciplinary complex will provide 150 labs for the study of inflammation, infection, and immunology. The structure will also accommodate collaborative workspaces, instrumentation suites, research offices, and interaction zones.
AstraZeneca is planning to expand its Hurdsfield campus with the construction of a 95,000-sf pharmaceutical manufacturing facility. Accommodating 72 new employees, Building 52 will occupy a remediated brownfield site in Macclesfield in the United Kingdom. The two-story structure will provide leading-edge formulation suites and production lines for the manufacture of prescription medicines.
Grand River Aseptic Manufacturing (GRAM) opened a $60 million facility for injectable fill-and-finish operations in June of 2020. Tripling GRAM's existing footprint in Grand Rapids, Mich., the 61,500-sf expansion provides a Grade C cleanroom, two formulation suites, and 14,000 sf of shell space to accommodate future growth. The facility leverages leading-edge automation technologies and high-speed instrumentation to accelerate the production of parenteral therapies. The project was delivered in just 20 months by design-build contractor CRB.
Trammell Crow Company will break ground in July of 2020 on Fulton Labs in Chicago. Providing wet and dry research environments, the 16-story, 423,454-sf life science facility will offer column-free and long-span layouts as well as a dedicated innovation floor for early-stage companies. Designed for maximum flexibility and scalability, the 16-story structure will integrate advanced mechanical infrastructure to support advanced R&D enterprises, with all labs meeting VC-A vibration criteria to ensure reproducible research results.
Sanofi Pasteur is planning to create the Evolutive Vaccine Facility (EVF) in Neuville sur Saône, France. Representing an investment of €490 million over a five-year period, the structure will house a central unit containing several fully digital production modules, enabling the manufacture of four vaccines simultaneously. This modularity will make it possible to prioritize the delivery of a specific vaccine to address crucial public health issues. The company will also invest €120 million to construct a new R&D center in Marcy-l'Etoile.
The South Australian Health and Medical Research Institute will begin construction in July of 2020 on the SAHMRI 2 building in Adelaide. Designed by Woods Bagot, the AUD$500 million project will accelerate the delivery of leading-edge clinical care as well as accommodating growing research programs in health analytics, artificial intelligence, and machine learning. Standing 12 stories above grade with three underground levels, the facility will house the Australian Bragg Centre for Proton Therapy & Research and the SAiGEN Cancer Institute.
